End Use Scope Segment Analysis: Biopharmaceutical & Pharmaceutical Companies (Largest Segment) vs CROs & CMOs (Fastest-Growing Segment)

Biopharmaceutical & pharmaceutical companies accounted for the largest share of the cell therapy raw materials market at 56.05% in 2026, reflecting their central role in developing and manufacturing cell-based therapies. Reliable raw materials are essential for maintaining cell viability, consistency, and reproducibility throughout research, process development, and production activities. The expanding pipeline of cell therapies and increasing emphasis on controlled manufacturing processes are driving demand for specialized inputs that meet stringent quality and performance requirements. Greater investment in advanced therapeutic platforms is therefore sustaining strong purchasing activity from pharmaceutical and biopharmaceutical developers.

CROs & CMOs are emerging as the fastest-growing end-use segment as cell therapy developers increasingly rely on external partners for research, process development, manufacturing, and specialized testing activities. Outsourcing enables therapy developers to access specialized infrastructure and technical expertise while improving operational flexibility and reducing the need for extensive internal capabilities. As cell therapy manufacturing becomes more complex, the growing use of external development and manufacturing partners is supporting broader demand for standardized, high-quality raw materials across outsourced workflows.

Product Scope Segment Analysis: Cell Culture Supplements (Largest Segment) vs Media (Fastest-Growing Segment)

Cell culture supplements held the largest share of the cell therapy raw materials market at 27.19% in 2026, supported by their essential role in maintaining cell growth, viability, proliferation, and functional characteristics during cell culture. These inputs are particularly important in workflows where consistent cellular performance is required for therapeutic development and manufacturing. Increasing adoption of cell-based research and therapies is strengthening demand for specialized supplements capable of supporting reproducible culture conditions and meeting increasingly stringent process requirements.

Media is expected to experience the fastest growth as cell therapy developers place greater emphasis on optimized culture environments that can improve consistency, scalability, and cell performance. Advances in cell culture processes are encouraging the development and adoption of media formulations tailored to specific cell types and therapeutic applications. The shift toward more controlled and scalable manufacturing systems, together with increasing requirements for process reproducibility, is creating favorable conditions for expanded use of specialized media.